{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:36:41Z","timestamp":1790638601552,"version":"4.1.0"},"reference-count":330,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018231","name":"Aligning Science Across Parkinson's","doi-asserted-by":"publisher","award":["ASAP-020505"],"award-info":[{"award-number":["ASAP-020505"]}],"id":[{"id":"10.13039\/100018231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI2018-098432-BI00"],"award-info":[{"award-number":["RTI2018-098432-BI00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-116339RB-I00"],"award-info":[{"award-number":["PID2020-116339RB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PI22\/00427"],"award-info":[{"award-number":["PI22\/00427"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-143110OB-100"],"award-info":[{"award-number":["PID2022-143110OB-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CONVREC-2021-278"],"award-info":[{"award-number":["CONVREC-2021-278"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PI20\/01399"],"award-info":[{"award-number":["PI20\/01399"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-125909OB-100"],"award-info":[{"award-number":["PID2021-125909OB-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Mutua Madrile\u00f1a Foundation","doi-asserted-by":"publisher","award":["FMM2020"],"award-info":[{"award-number":["FMM2020"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Ramon Areces Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007515","name":"Universidad de Valladolid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023731","name":"Regional Government of Andalusia Ministry of Health and Consumer Affairs","doi-asserted-by":"publisher","award":["PI-232-2022"],"award-info":[{"award-number":["PI-232-2022"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["CTS-677"],"award-info":[{"award-number":["CTS-677"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["RTI2018-098432-BI00"],"award-info":[{"award-number":["RTI2018-098432-BI00"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007747","name":"Spanish Multiple Sclerosis Network","doi-asserted-by":"publisher","award":["050601240006"],"award-info":[{"award-number":["050601240006"]}],"id":[{"id":"10.13039\/501100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["CIAICO\/2024\/313"],"award-info":[{"award-number":["CIAICO\/2024\/313"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Government of Castile and Le\u00f3n","doi-asserted-by":"publisher","award":["CCVC8485"],"award-info":[{"award-number":["CCVC8485"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Government of Castile and Le\u00f3n","doi-asserted-by":"publisher","award":["CL-EI-2021-09"],"award-info":[{"award-number":["CL-EI-2021-09"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PI2020\/09"],"award-info":[{"award-number":["PI2020\/09"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-120308RB"],"award-info":[{"award-number":["PID2020-120308RB"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.apsb.2026.03.031","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:38:40Z","timestamp":1774035520000},"page":"2645-2681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations"],"prefix":"10.1016","volume":"16","author":[{"given":"Ana Lizeth","family":"Padilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Lanciego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-8032","authenticated-orcid":false,"given":"Fernando","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodr\u00edguez de Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"S\u00e1ez-Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1783-7320","authenticated-orcid":false,"given":"Victor","family":"Tapias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.03.031_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.03.031_bib2","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.apsb.2024.01.015","article-title":"The raphe nuclei are the early lesion site of gastric alpha-synuclein propagation to the substantia nigra","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.031_bib3","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.apsb.2023.03.011","article-title":"Corynoxine B targets at HMGB1\/2 to enhance autophagy for alpha-synuclein clearance in fly and rodent models of Parkinson's disease","volume":"13","author":"Zhu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.031_bib4","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1038\/ncomms4827","article-title":"Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour","volume":"5","author":"Fusco","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41467-018-03111-4","article-title":"C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction","volume":"9","author":"Lautenschlager","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib6","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1523\/JNEUROSCI.1659-16.2016","article-title":"Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase","volume":"36","author":"Ludtmann","year":"2016","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting alpha-synuclein for Parkinson's disease","volume":"74","author":"Grosso","year":"2022","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2026.03.031_bib8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/pharmrev.123.001111","article-title":"Posttranslational modifications of alpha-synuclein, their therapeutic potential, and crosstalk in health and neurodegenerative diseases","volume":"76","author":"Hassanzadeh","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2026.03.031_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrn2477","article-title":"Research in motion: the enigma of Parkinson's disease pathology spread","volume":"9","author":"Brundin","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s40478-020-01090-6","article-title":"Isotope-reinforced polyunsaturated fatty acids improve Parkinson's disease-like phenotype in rats overexpressing alpha-synuclein","volume":"8","author":"Beal","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib11","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00018-017-2541-x","article-title":"Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production","volume":"74","author":"Tapias","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib12","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.031_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jnen\/63.4.329","article-title":"Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers","volume":"63","author":"Beach","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41531-024-00754-7","article-title":"The digital signature of emergent tremor in Parkinson's disease","volume":"10","author":"Gala","year":"2024","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/brain\/awp328","article-title":"The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease","volume":"133","author":"Grealish","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41586-024-08038-z","article-title":"Dopamine dynamics are dispensable for movement but promote reward responses","volume":"635","author":"Cai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2024.12.031","article-title":"Contextual cues facilitate dynamic value encoding in the mesolimbic dopamine system","volume":"35","author":"Fraser","year":"2025","journal-title":"Curr Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2026.03.031_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/ene.13919","article-title":"Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease","volume":"26","author":"Durcan","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","article-title":"The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study)","volume":"30","author":"Pont-Sunyer","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib22","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/sj.emboj.7601656","article-title":"Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor","volume":"26","author":"Lee","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2026.03.031_bib23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/pr.114.010397","article-title":"Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease","volume":"67","author":"German","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2026.03.031_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13024-019-0332-6","article-title":"Impaired dopamine metabolism in Parkinson's disease pathogenesis","volume":"14","author":"Masato","year":"2019","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2026.03.031_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.105925","article-title":"Altered transcriptome\u2013proteome coupling indicates aberrant proteostasis in Parkinson's disease","volume":"26","author":"Dick","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.apsb.2026.03.031_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-025-03462-y","article-title":"Microglial dynamics and neuroinflammation in prodromal and early Parkinson's disease","volume":"22","author":"Lind-Holm Mogensen","year":"2025","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.apsb.2026.03.031_bib27","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/brain\/awae177","article-title":"The immune system in Parkinson's disease: what we know so far","volume":"147","author":"Roodveldt","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib28","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/brain\/awab446","article-title":"Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state","volume":"145","author":"Smajic","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/S031716710003849X","article-title":"Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients","volume":"23","author":"Blanchet","year":"1996","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson's disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.apsb.2026.03.031_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41531-024-00812-0","article-title":"Randomized crossover trial on motor and non-motor outcome of directional deep brain stimulation in Parkinson's disease","volume":"10","author":"Gharabaghi","year":"2024","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105318","article-title":"Non-motor effects of deep brain stimulation in Parkinson's disease motor subtypes","volume":"109","author":"Jost","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib35","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1038\/s41598-024-57030-0","article-title":"Transcranial static magnetic field stimulation of the supplementary motor area decreases corticospinal excitability in the motor cortex: a pilot study","volume":"14","author":"Pagge","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.brs.2022.05.012","article-title":"Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: a randomized controlled trial","volume":"15","author":"Dileone","year":"2022","journal-title":"Brain Stimul"},{"key":"10.1016\/j.apsb.2026.03.031_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41531-019-0105-5","article-title":"Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease","volume":"6","author":"Harris","year":"2020","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib38","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1038\/s41467-022-30777-8","article-title":"Robust derivation of transplantable dopamine neurons from human pluripotent stem cells by timed retinoic acid delivery","volume":"13","author":"Alekseenko","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib39","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/cells11101596","article-title":"Long-term evaluation of intranigral transplantation of human iPSC-derived dopamine neurons in a Parkinson's disease mouse model","volume":"11","author":"Brot","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.031_bib40","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1038\/s41467-020-17165-w","article-title":"Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease","volume":"11","author":"Doi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nature23664","article-title":"Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model","volume":"548","author":"Kikuchi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib42","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1172\/JCI130767","article-title":"Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models","volume":"130","author":"Song","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.031_bib43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-021-01257-1","article-title":"Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys","volume":"27","author":"Tao","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib44","article-title":"Induced cognitive impairments reversed by grafts of neural precursors: a longitudinal study in a macaque model of Parkinson's disease","volume":"9","author":"Wianny","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.03.031_bib45","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","article-title":"Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease","volume":"25","author":"Barker","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib46","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1073\/pnas.1605245113","article-title":"Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain","volume":"113","author":"Li","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib47","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/brain\/awh510","article-title":"Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease","volume":"128","author":"Mendez","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ana.410420115","article-title":"Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease","volume":"42","author":"Wenning","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib49","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","article-title":"Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease","volume":"641","author":"Sawamoto","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib50","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","article-title":"Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease","volume":"382","author":"Schweitzer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.reth.2020.06.002","article-title":"iPS cell-based therapy for Parkinson's disease: a Kyoto trial","volume":"13","author":"Takahashi","year":"2020","journal-title":"Regen Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1227\/01.NEU.0000073315.88827.72","article-title":"Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease","volume":"53","author":"Arjona","year":"2003","journal-title":"Neurosurgery"},{"key":"10.1016\/j.apsb.2026.03.031_bib53","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/jnnp.2006.106021","article-title":"Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study","volume":"78","author":"Minguez-Castellanos","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.apsb.2026.03.031_bib54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00109-021-02059-1","article-title":"Cell-based drug delivery harnesses inflammatory and autoimmune responses in neurodegeneration","volume":"99","author":"Pozo","year":"2021","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.apsb.2026.03.031_bib55","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trsl.2009.07.006","article-title":"Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease","volume":"155","author":"Venkataramana","year":"2010","journal-title":"Transl Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib56","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of hypoimmunogenic human pluripotent stem cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib57","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s12276-025-01422-3","article-title":"Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout","volume":"57","author":"Kim","year":"2025","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41598-018-35811-8","article-title":"Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose","volume":"9","author":"Hoffmann","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib59","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fnins.2018.00452","article-title":"Region-specific effects of immunotherapy with antibodies targeting alpha-synuclein in a transgenic model of synucleinopathy","volume":"12","author":"Kallab","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib60","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s13287-022-03139-w","article-title":"Priming mesenchymal stem cells with alpha-synuclein enhances neuroprotective properties through induction of autophagy in Parkinsonian models","volume":"13","author":"Shin","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib62","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.apsb.2021.02.016","article-title":"Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.031_bib63","doi-asserted-by":"crossref","DOI":"10.1088\/1741-2552\/ad33b2","article-title":"Survival and maturation of human induced pluripotent stem cell-derived dopaminergic progenitors in the parkinsonian rat brain is enhanced by transplantation in a neurotrophin-enriched hydrogel","volume":"21","author":"Comini","year":"2024","journal-title":"J Neural Eng"},{"key":"10.1016\/j.apsb.2026.03.031_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/ten.tea.2019.0094","article-title":"Peptide-based scaffolds for the culture and transplantation of human dopaminergic neurons","volume":"26","author":"Francis","year":"2020","journal-title":"Tissue Eng Part A"},{"key":"10.1016\/j.apsb.2026.03.031_bib65","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ejn.14090","article-title":"Encapsulation of young donor age dopaminergic grafts in a GDNF-loaded collagen hydrogel further increases their survival, reinnervation, and functional efficacy after intrastriatal transplantation in hemi-Parkinsonian rats","volume":"49","author":"Moriarty","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115429","article-title":"Drug delivery strategies for local immunomodulation in transplantation: bridging the translational gap","volume":"213","author":"Naaz","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.03.031_bib67","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cell.2009.02.013","article-title":"Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors","volume":"136","author":"Soldner","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib68","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/s41467-021-25482-x","article-title":"Cell reprogramming shapes the mitochondrial DNA landscape","volume":"12","author":"Wei","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib69","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.21873\/invivo.13300","article-title":"Therapeutic effect of human adipocyte-derived stem cell-derived exosomes on a transgenic mouse model of Parkinson's disease","volume":"37","author":"Chan","year":"2023","journal-title":"In Vivo (Athens)"},{"key":"10.1016\/j.apsb.2026.03.031_bib70","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13287-025-04457-5","article-title":"Mesenchymal stem cell-derived exosomes-a promising therapeutic approach to improve neurocognitive disorders in chronic obstructive pulmonary disease","volume":"16","author":"Xiao","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40035-020-00190-6","article-title":"Human iPSCs derived astrocytes rescue rotenone-induced mitochondrial dysfunction and dopaminergic neurodegeneration in vitro by donating functional mitochondria","volume":"9","author":"Cheng","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.apsb.2026.03.031_bib72","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","article-title":"Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease","volume":"16","author":"Hallett","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib73","doi-asserted-by":"crossref","first-page":"41211","DOI":"10.1074\/jbc.C110.193904","article-title":"Axonal degeneration is blocked by nicotinamide mononucleotide adenylyltransferase (Nmnat) protein transduction into transected axons","volume":"285","author":"Sasaki","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.03.031_bib74","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1073\/pnas.0909794107","article-title":"Mechanisms of acute axonal degeneration in the optic nerve in vivo","volume":"107","author":"Knoferle","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.169","article-title":"Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons","volume":"6","author":"Koch","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib76","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson's disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib77","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/brain\/awn332","article-title":"Motor axon excitability during Wallerian degeneration","volume":"132","author":"Moldovan","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.201108111","article-title":"Axon degeneration: molecular mechanisms of a self-destruction pathway","volume":"196","author":"Wang","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib79","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib80","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1523\/JNEUROSCI.4029-08.2009","article-title":"Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum","volume":"29","author":"Matsuda","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib81","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/mds.25135","article-title":"Living on the edge with too many mouths to feed: why dopamine neurons die","volume":"27","author":"Bolam","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib82","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1002\/cne.24288","article-title":"Characterization of the axon initial segment of mice substantia nigra dopaminergic neurons","volume":"525","author":"Gonzalez-Cabrera","year":"2017","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib83","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.neuron.2008.01.022","article-title":"Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system","volume":"57","author":"Lammel","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2026.03.031_bib84","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1523\/JNEUROSCI.2969-16.2017","article-title":"Enhanced sensitivity to hyperpolarizing inhibition in mesoaccumbal relative to nigrostriatal dopamine neuron subpopulations","volume":"37","author":"Tarfa","year":"2017","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib85","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Curr Biol"},{"issue":"Pt 8","key":"10.1016\/j.apsb.2026.03.031_bib86","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib87","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/mdc3.13687","article-title":"Striatal dopamine loss in early Parkinson's disease: systematic review and novel analysis of dopamine transporter imaging","volume":"10","author":"Heng","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.apsb.2026.03.031_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73777-y","article-title":"Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes","volume":"14","author":"Houot","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.parkreldis.2020.06.019","article-title":"DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: longitudinal data from the PPMI study","volume":"77","author":"Koros","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/syn.890130402","article-title":"SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates","volume":"13","author":"Laruelle","year":"1993","journal-title":"Synapse"},{"key":"10.1016\/j.apsb.2026.03.031_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1095761","article-title":"In vivo 18F-DOPA PET imaging identifies a dopaminergic deficit in a rat model with a G51D alpha-synuclein mutation","volume":"17","author":"Morley","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib94","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/mds.1139","article-title":"Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study","volume":"16","author":"Nurmi","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib95","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.neuroimage.2011.03.012","article-title":"Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study","volume":"56","author":"Pavese","year":"2011","journal-title":"Neuroimage"},{"key":"10.1016\/j.apsb.2026.03.031_bib96","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199211263272202","article-title":"Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease","volume":"327","author":"Freed","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib97","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1126\/science.2105529","article-title":"Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease","volume":"247","author":"Lindvall","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.031_bib98","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ana.25682","article-title":"Synaptic changes in Parkinson disease assessed with in vivo imaging","volume":"87","author":"Matuskey","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/exnr.1999.7089","article-title":"Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys","volume":"158","author":"Chen","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41598-020-80836-7","article-title":"Fast 3 T nigral hyperintensity magnetic resonance imaging in Parkinson's disease","volume":"11","author":"Hernadi","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41531-018-0047-3","article-title":"Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease","volume":"4","author":"Sulzer","year":"2018","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib102","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1073\/pnas.89.15.7095","article-title":"Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age","volume":"89","author":"Bannon","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib103","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mds.870120609","article-title":"Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease","volume":"12","author":"Joyce","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib104","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0006-8993(93)91005-D","article-title":"Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease","volume":"606","author":"Kastner","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ana.410410417","article-title":"Immunochemical analysis of dopamine transporter protein in Parkinson's disease","volume":"41","author":"Miller","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib106","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pharmrev.120.000189","article-title":"Parkinson disease: translating insights from molecular mechanisms to neuroprotection","volume":"73","author":"Pirooznia","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2026.03.031_bib107","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","article-title":"Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations","volume":"19","author":"Goetz","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2026.03.031_bib109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo parkinson disease from the Parkinson's progression markers initiative cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.apsb.2026.03.031_bib110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2026.03.031_bib111","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/pharmrev.121.000418","article-title":"Therapeutic opportunities and delivery strategies for brain revascularization in stroke, neurodegeneration, and aging","volume":"74","author":"Gallego","year":"2022","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2026.03.031_bib112","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","article-title":"Dopamine neuron systems in the brain: an update","volume":"30","author":"Bjorklund","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib113","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/289497a0","article-title":"Functional reactivation of the deafferented neostriatum by nigral transplants","volume":"289","author":"Bjorklund","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.expneurol.2017.01.010","article-title":"Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats","volume":"291","author":"Fjodorova","year":"2017","journal-title":"Exp Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2026.03.031_bib115","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.surneu.2005.07.038","article-title":"Effects of intranigral vs intrastriatal fetal mesencephalic neural grafts on motor behavior disorders in a rat Parkinson model","volume":"64","author":"Goren","year":"2005","journal-title":"Surg Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib116","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0006-8993(94)91532-6","article-title":"Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model","volume":"633","author":"Nikkhah","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib117","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.571147","article-title":"Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system","volume":"204","author":"Perlow","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.031_bib118","first-page":"358","article-title":"Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates","volume":"48","author":"Bakay","year":"1985","journal-title":"Appl Neurophysiol"},{"key":"10.1016\/j.apsb.2026.03.031_bib119","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)60321-0","article-title":"Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"78","author":"Fine","year":"1988","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0361-9230(86)90092-4","article-title":"Survival and growth of fetal catecholamine neurons transplanted into primate brain","volume":"17","author":"Sladek","year":"1986","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.apsb.2026.03.031_bib121","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/exnr.1997.6577","article-title":"Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue","volume":"146","author":"Kopyov","year":"1997","journal-title":"Exp Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib122","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199504273321702","article-title":"Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease","volume":"332","author":"Kordower","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib123","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2967\/jnumed.109.066811","article-title":"Dopamine cell implantation in Parkinson's disease: long-term clinical and 18F-FDOPA PET outcomes","volume":"51","author":"Ma","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib124","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe Parkinson's disease","volume":"344","author":"Freed","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib126","first-page":"70","article-title":"The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease","volume":"10","author":"Barker","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.03.031_bib127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaneurol.2013.4749","article-title":"Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports","volume":"71","author":"Kefalopoulou","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib128","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.nbd.2011.05.001","article-title":"Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat","volume":"43","author":"Kordower","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/096368979700600304","article-title":"Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants","volume":"6","author":"Kordower","year":"1997","journal-title":"Cell Transplant"},{"key":"10.1016\/j.apsb.2026.03.031_bib130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13287-024-03965-0","article-title":"The therapeutic use of clonal neural stem cells in experimental Parkinson s disease","volume":"15","author":"Nelke","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"Suppl 3","key":"10.1016\/j.apsb.2026.03.031_bib131","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00415-009-5242-z","article-title":"Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients","volume":"256","author":"Cooper","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib132","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib133","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/mds.22369","article-title":"Transplanted dopaminergic neurons develop PD pathologic changes: a second case report","volume":"23","author":"Kordower","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib134","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/JPD-2011-11004","article-title":"Signs of degeneration in 12\u201322-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease","volume":"1","author":"Kurowska","year":"2011","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib136","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.parkreldis.2019.12.013","article-title":"Co-Existence of tau and alpha-synuclein pathology in fetal graft tissue at autopsy: a case report","volume":"71","author":"Ornelas","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib137","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuron.2005.06.027","article-title":"The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses","volume":"47","author":"Guo","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2026.03.031_bib138","doi-asserted-by":"crossref","first-page":"18977","DOI":"10.1073\/pnas.2006291117","article-title":"Unroofing site-specific alpha-synuclein\u2013lipid interactions at the plasma membrane","volume":"117","author":"Kaur","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib139","article-title":"Mechanistic basis for receptor-mediated pathological alpha-synuclein fibril cell-to-cell transmission in Parkinson's disease","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13024-021-00497-6","article-title":"Small molecule inhibitors of alpha-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans","volume":"16","author":"Chen","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2026.03.031_bib141","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41589-024-01580-x","article-title":"Discovery of potent inhibitors of alpha-synuclein aggregation using structure-based iterative learning","volume":"20","author":"Horne","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib142","doi-asserted-by":"crossref","first-page":"24310","DOI":"10.1073\/pnas.1903268116","article-title":"Hsp110 mitigates alpha-synuclein pathology in vivo","volume":"116","author":"Taguchi","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib143","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40035-023-00363-z","article-title":"Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models","volume":"12","author":"Drobny","year":"2023","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.apsb.2026.03.031_bib144","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-023-00630-7","article-title":"Targeted degradation of \u03b1-synuclein aggregates in Parkinson's disease using the AUTOTAC technology","volume":"18","author":"Lee","year":"2023","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2026.03.031_bib145","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1523\/JNEUROSCI.1676-05.2005","article-title":"Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections","volume":"25","author":"Thompson","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib146","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13287-025-04344-z","article-title":"Electrophysiological characterisation of intranigral-grafted hiPSC-derived dopaminergic neurons in a mouse model of Parkinson's disease","volume":"16","author":"Ballion","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib147","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41536-022-00221-y","article-title":"Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease","volume":"7","author":"Hiller","year":"2022","journal-title":"npj Regen Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107833","article-title":"Allogenic transplantation therapy of iPS cell-derived dopamine progenitors for Parkinson's disease\u2014current status of the Kyoto Trial and future perspectives","volume":"135","author":"Takahashi","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib149","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/sctm.20-0177","article-title":"Enhanced differentiation of human induced pluripotent stem cells toward the midbrain dopaminergic neuron lineage through GLYPICAN-4 downregulation","volume":"10","author":"Corti","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib150","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1038\/s41598-017-05633-1","article-title":"Expansion of human midbrain floor plate progenitors from induced pluripotent stem cells increases dopaminergic neuron differentiation potential","volume":"7","author":"Fedele","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib151","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.stemcr.2017.09.024","article-title":"Escape from pluripotency via inhibition of TGF-beta\/BMP and activation of Wnt signaling accelerates differentiation and aging in hPSC progeny cells","volume":"9","author":"Fujimori","year":"2017","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib152","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10648","article-title":"Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease","volume":"480","author":"Kriks","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib153","doi-asserted-by":"crossref","first-page":"15921","DOI":"10.1073\/pnas.1010209107","article-title":"Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats","volume":"107","author":"Hargus","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib154","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1172\/JCI45794","article-title":"Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease","volume":"121","author":"Rhee","year":"2011","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.031_bib155","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2015.12","article-title":"Autologous iPSC-derived dopamine neuron transplantation in a nonhuman primate Parkinson's disease model","volume":"1","author":"Wang","year":"2015","journal-title":"Cell Discov"},{"key":"10.1016\/j.apsb.2026.03.031_bib156","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41467-017-00926-5","article-title":"MHC matching improves engraftment of iPSC-derived neurons in non-human primates","volume":"8","author":"Morizane","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib157","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3727\/096368916X691682","article-title":"Neural stem cells derived from human parthenogenetic stem cells engraft and promote recovery in a nonhuman primate model of Parkinson's disease","volume":"25","author":"Gonzalez","year":"2016","journal-title":"Cell Transplant"},{"key":"10.1016\/j.apsb.2026.03.031_bib158","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature10284","article-title":"Direct generation of functional dopaminergic neurons from mouse and human fibroblasts","volume":"476","author":"Caiazzo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib159","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4103\/1673-5374.378203","article-title":"Multiple factors to assist human-derived induced pluripotent stem cells to efficiently differentiate into midbrain dopaminergic neurons","volume":"19","author":"Chen","year":"2024","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib160","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.3390\/ijms21165705","article-title":"Origin of the induced pluripotent stem cells affects their differentiation into dopaminergic neurons","volume":"21","author":"Chlebanowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib161","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.stemcr.2019.12.002","article-title":"Transdifferentiation of mouse embryonic fibroblasts into dopaminergic neurons reactivates LINE-1 repetitive elements","volume":"14","author":"Della Valle","year":"2020","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib162","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41596-021-00673-4","article-title":"Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells","volume":"17","author":"Kim","year":"2022","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2026.03.031_bib163","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.3390\/ijms24087297","article-title":"An efficient 2D protocol for differentiation of iPSCs into mature postmitotic dopaminergic neurons: application for modeling Parkinson's disease","volume":"24","author":"Lebedeva","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib164","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1038\/s41380-022-01628-1","article-title":"Generation of human A9 dopaminergic pacemakers from induced pluripotent stem cells","volume":"27","author":"Li","year":"2022","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.apsb.2026.03.031_bib165","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41419-019-2133-9","article-title":"Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors","volume":"10","author":"Mahajani","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib166","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1038\/s41467-023-43471-0","article-title":"Enhanced production of mesencephalic dopaminergic neurons from lineage-restricted human undifferentiated stem cells","volume":"14","author":"Maimaitili","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib167","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1202027","article-title":"A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson's disease","volume":"17","author":"Nakamura","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib168","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.stemcr.2021.05.017","article-title":"Efficient generation of dopaminergic induced neuronal cells with midbrain characteristics","volume":"16","author":"Ng","year":"2021","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib169","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/nprot.2017.078","article-title":"Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation","volume":"12","author":"Nolbrant","year":"2017","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2026.03.031_bib170","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1073\/pnas.1105135108","article-title":"Direct conversion of human fibroblasts to dopaminergic neurons","volume":"108","author":"Pfisterer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib171","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40779-020-00284-2","article-title":"Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors","volume":"7","author":"Qin","year":"2020","journal-title":"Milit Med Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib172","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s13287-024-04073-9","article-title":"Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's disease","volume":"15","author":"Ekrani","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib173","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41531-022-00440-6","article-title":"Genetically engineered mesenchymal stem cells with dopamine synthesis for Parkinson's disease in animal models","volume":"8","author":"Li","year":"2022","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib174","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41536-020-00106-y","article-title":"Challenges and translational considerations of mesenchymal stem\/stromal cell therapy for Parkinson's disease","volume":"5","author":"Fricova","year":"2020","journal-title":"npj Regen Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005222","article-title":"Chemically-induced RAT mesenchymal stem cells adopt molecular properties of neuronal-like cells but do not have basic neuronal functional properties","volume":"4","author":"Barnabe","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.03.031_bib176","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/jnr.23879","article-title":"Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease","volume":"95","author":"Chen","year":"2017","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib177","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1038\/s41598-019-39544-0","article-title":"Forskolin and IBMX induce neural transdifferentiation of MSCs through downregulation of the NRSF","volume":"9","author":"Thompson","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib178","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3940(01)02384-9","article-title":"Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"316","author":"Li","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.apsb.2026.03.031_bib179","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.neuint.2008.02.003","article-title":"Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease","volume":"52","author":"Bouchez","year":"2008","journal-title":"Neurochem Int"},{"key":"10.1016\/j.apsb.2026.03.031_bib180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jcyt.2014.09.005","article-title":"Human adipose-derived mesenchymal stromal cells increase endogenous neurogenesis in the rat subventricular zone acutely after 6-hydroxydopamine lesioning","volume":"17","author":"Schwerk","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.apsb.2026.03.031_bib181","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.biomaterials.2010.10.041","article-title":"The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats","volume":"32","author":"Delcroix","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.03.031_bib182","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1111\/jcmm.16900","article-title":"Dose-dependent effect of mesenchymal stromal cells co-grafted with dopaminergic neurons in a Parkinson's disease rat model","volume":"25","author":"Rodriguez-Pallares","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib183","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1523\/JNEUROSCI.23-01-00141.2003","article-title":"Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats","volume":"23","author":"Toledo-Aral","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib184","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1523\/JNEUROSCI.4312-04.2005","article-title":"Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation","volume":"25","author":"Villadiego","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib185","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0896-6273(00)80733-3","article-title":"Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen","volume":"22","author":"Luquin","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2026.03.031_bib186","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.neurobiolaging.2012.06.001","article-title":"Neuroprotective and reparative effects of carotid body grafts in a chronic MPTP model of Parkinson's disease","volume":"34","author":"Munoz-Manchado","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2026.03.031_bib187","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0896-6273(00)80449-3","article-title":"Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates","volume":"20","author":"Espejo","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2026.03.031_bib188","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.brainres.2010.12.033","article-title":"Enhanced GDNF expression in dopaminergic cells of monkeys grafted with carotid body cell aggregates","volume":"1375","author":"Luquin","year":"2011","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib189","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00109-019-01776-y","article-title":"Current understanding of the immunosuppressive properties of mesenchymal stromal cells","volume":"97","author":"de Castro","year":"2019","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.apsb.2026.03.031_bib190","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3389\/fimmu.2020.01076","article-title":"Immunosuppressive property of MSCs mediated by cell surface receptors","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.031_bib191","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/1570159X20666220327212414","article-title":"Mechanism of mesenchymal stem cells as a multitarget disease-modifying therapy for Parkinson's disease","volume":"21","author":"Unnisa","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.apsb.2026.03.031_bib192","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/cells10081953","article-title":"An electrophysiological and pharmacological study of the properties of human iPSC-derived neurons for drug discovery","volume":"10","author":"Halliwell","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.031_bib193","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.817198","article-title":"Electrophysiological properties of induced pluripotent stem cell-derived midbrain dopaminergic neurons correlate with expression of tyrosine hydroxylase","volume":"16","author":"Rakovic","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib194","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.7150\/thno.80271","article-title":"Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease","volume":"13","author":"Zheng","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2026.03.031_bib195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017560","article-title":"Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model","volume":"6","author":"Tonnesen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.03.031_bib196","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3124","article-title":"Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model","volume":"33","author":"Steinbeck","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.03.031_bib197","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00702-015-1405-5","article-title":"Neuropathobiology of non-motor symptoms in Parkinson disease","volume":"122","author":"Jellinger","year":"2015","journal-title":"J Neural Transm"},{"key":"10.1016\/j.apsb.2026.03.031_bib198","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/cells13151265","article-title":"Alpha synuclein toxicity and non-motor Parkinson's","volume":"13","author":"Mazzotta","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.031_bib199","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neuroscience.2018.01.032","article-title":"Cognitive flexibility deficits following 6-OHDA lesions of the rat dorsomedial striatum","volume":"374","author":"Grospe","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2026.03.031_bib200","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.neuropharm.2018.11.040","article-title":"Dissociative effects of dorsomedial striatum D1 and D2 receptor antagonism in the regulation of anxiety and learned approach-avoidance conflict decision-making","volume":"146","author":"Nguyen","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.apsb.2026.03.031_bib201","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/s41386-019-0454-0","article-title":"Differential contributions of striatal dopamine D1 and D2 receptors to component processes of value-based decision making","volume":"44","author":"Verharen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.apsb.2026.03.031_bib202","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jneumeth.2005.04.005","article-title":"Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations","volume":"148","author":"Ferro","year":"2005","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.apsb.2026.03.031_bib203","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neuroscience.2008.08.035","article-title":"Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease","volume":"156","author":"Tadaiesky","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2026.03.031_bib204","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.pnpbp.2010.06.004","article-title":"Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine","volume":"34","author":"Santiago","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.apsb.2026.03.031_bib205","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbr.2018.12.007","article-title":"Implication of nigral dopaminergic lesion and repeated l-dopa exposure in neuropsychiatric symptoms of Parkinson's disease","volume":"360","author":"Loiodice","year":"2019","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib206","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awf052","article-title":"Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET","volume":"125","author":"Cools","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib207","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/brain\/awz276","article-title":"Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson's disease","volume":"142","author":"McCoy","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib208","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.neuropsychologia.2017.12.032","article-title":"Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease","volume":"109","author":"Wylie","year":"2018","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.apsb.2026.03.031_bib209","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib210","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.948848","article-title":"Assessment of the anti-nociceptive effects of fetal ventral mesencephalic tissue allografts in a rat model of hemi-Parkinson's disease using fMRI","volume":"14","author":"Chiu","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib211","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.expneurol.2016.02.003","article-title":"Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease","volume":"278","author":"Lelos","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib212","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archneur.1995.00540310050016","article-title":"General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease","volume":"52","author":"Sass","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib213","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1212\/01.WNL.0000070181.28651.3B","article-title":"Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study","volume":"60","author":"Trott","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2026.03.031_bib214","doi-asserted-by":"crossref","first-page":"380","DOI":"10.25259\/SNI_233_2020","article-title":"Mesenchymal stem cells in Parkinson's disease: motor and nonmotor symptoms in the early posttransplant period","volume":"11","author":"Boika","year":"2020","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.apsb.2026.03.031_bib215","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF00414167","article-title":"Immunohistochemical and histochemical evidence for the presence of noradrenaline, serotonin and gamma-aminobutyric acid in chief cells of the mouse carotid body","volume":"278","author":"Oomori","year":"1994","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib216","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","article-title":"Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression","volume":"132","author":"Riederer","year":"2025","journal-title":"J Neural Transm"},{"key":"10.1016\/j.apsb.2026.03.031_bib217","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/mds.23743","article-title":"Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin\/dopamine transporter ratio","volume":"26","author":"Politis","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib218","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/mdc3.13962","article-title":"How to use the New European Academy of Neurology\/Movement Disorder Society European Section Guideline for invasive therapies in Parkinson's disease","volume":"11","author":"Brinker","year":"2024","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.apsb.2026.03.031_bib219","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41597-024-03356-3","article-title":"A longitudinal electrophysiological and behavior dataset for PD rat in response to deep brain stimulation","volume":"11","author":"Wang","year":"2024","journal-title":"Sci Data"},{"key":"10.1016\/j.apsb.2026.03.031_bib220","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41591-024-03196-z","article-title":"Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial","volume":"30","author":"Oehrn","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib221","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2025.03.030","article-title":"Recent developments in gene therapy for Parkinson's disease","volume":"33","author":"Szunyogh","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123268","article-title":"Biodegradable, electroconductive self-healing hydrogel based on polydopamine-coated polyurethane nano-crosslinker for Parkinson's disease therapy","volume":"320","author":"Chen","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.03.031_bib223","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib224","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease \u2014 a key disease hallmark with therapeutic potential","volume":"18","author":"Henrich","year":"2023","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2026.03.031_bib225","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fnins.2019.01372","article-title":"Editorial: mitochondrial dysfunction and neurodegeneration","volume":"13","author":"Tapias","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101164","article-title":"Phenothiazine normalizes the NADH\/NAD+ ratio, maintains mitochondrial integrity and protects the nigrostriatal dopamine system in a chronic rotenone model of Parkinson's disease","volume":"24","author":"Tapias","year":"2019","journal-title":"Redox Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib227","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbadis.2009.08.010","article-title":"Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases","volume":"1802","author":"Gibson","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2026.03.031_bib228","article-title":"PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson's disease","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib229","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1038\/s41467-022-33252-6","article-title":"Small soluble alpha-synuclein aggregates are the toxic species in Parkinson's disease","volume":"13","author":"Emin","year":"2022","journal-title":"Nat Commun"},{"issue":"Pt 2","key":"10.1016\/j.apsb.2026.03.031_bib230","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/brain\/115.2.333","article-title":"Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease","volume":"115","author":"Mann","year":"1992","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib231","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.brainres.2007.10.061","article-title":"Complex I deficiency in Parkinson's disease frontal cortex","volume":"1189","author":"Parker","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib232","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","article-title":"Mitochondrial complex I deficiency in Parkinson's disease","volume":"1","author":"Schapira","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.03.031_bib233","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.43.11.2258","article-title":"Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease","volume":"43","author":"Cardellach","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2026.03.031_bib234","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JPD-2011-11025","article-title":"Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication","volume":"1","author":"Mak","year":"2011","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02257619","article-title":"Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease","volume":"4","author":"Yoshino","year":"1992","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.apsb.2026.03.031_bib236","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41392-025-02253-4","article-title":"Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib237","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","article-title":"A highly reproducible rotenone model of Parkinson's disease","volume":"34","author":"Cannon","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib238","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1073\/pnas.0937239100","article-title":"NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease","volume":"100","author":"Wu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib239","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41392-023-01547-9","article-title":"Mitochondrial dynamics in health and disease: mechanisms and potential targets","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib240","doi-asserted-by":"crossref","first-page":"15927","DOI":"10.1073\/pnas.0407043101","article-title":"OPA1 requires mitofusin 1 to promote mitochondrial fusion","volume":"101","author":"Cipolat","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib241","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41586-018-0211-2","article-title":"Structural basis of mitochondrial receptor binding and constriction by DRP1","volume":"558","author":"Kalia","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib242","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tcb.2012.10.006","article-title":"Mitochondrial dynamics in neurodegeneration","volume":"23","author":"Itoh","year":"2013","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib243","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cmet.2015.06.006","article-title":"Redox homeostasis and mitochondrial dynamics","volume":"22","author":"Willems","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2026.03.031_bib244","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2004.11.003","article-title":"The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses","volume":"119","author":"Li","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib245","article-title":"Mfn2 is required for mitochondrial development and synapse formation in human induced pluripotent stem cells\/hiPSC derived cortical neurons","volume":"6","author":"Fang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib246","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuron.2005.06.018","article-title":"Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions","volume":"47","author":"Verstreken","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2026.03.031_bib247","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuint.2018.04.013","article-title":"Mitochondrial alterations in Parkinson's disease human samples and cellular models","volume":"118","author":"Zilocchi","year":"2018","journal-title":"Neurochem Int"},{"key":"10.1016\/j.apsb.2026.03.031_bib248","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1212\/WNL.0000000000003491","article-title":"Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations","volume":"88","author":"Liao","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2026.03.031_bib249","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1093\/hmg\/dds352","article-title":"Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons","volume":"21","author":"Lee","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apsb.2026.03.031_bib250","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1093\/hmg\/dds311","article-title":"Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit","volume":"21","author":"Pham","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apsb.2026.03.031_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174262","article-title":"Inhibition of dynamin-related protein 1 ameliorates the mitochondrial ultrastructure via PINK1 and Parkin in the mice model of Parkinson's disease","volume":"907","author":"Feng","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.031_bib252","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41580-022-00491-w","article-title":"Selective motor activation in organelle transport along axons","volume":"23","author":"Cason","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib253","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1126\/science.1204824","article-title":"The structure of the kinesin-1 motor-tail complex reveals the mechanism of autoinhibition","volume":"333","author":"Kaan","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.031_bib254","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.tibs.2020.02.002","article-title":"Activation and regulation of cytoplasmic dynein","volume":"45","author":"Canty","year":"2020","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib255","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0896-6273(02)01094-2","article-title":"Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila protein","volume":"36","author":"Stowers","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2026.03.031_bib256","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1523\/JNEUROSCI.5417-08.2009","article-title":"Drosophila Miro is required for both anterograde and retrograde axonal mitochondrial transport","volume":"29","author":"Russo","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib257","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1523\/JNEUROSCI.1472-09.2009","article-title":"Dynein light chain LC8 regulates syntaphilin-mediated mitochondrial docking in axons","volume":"29","author":"Chen","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib258","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/aws133","article-title":"Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease","volume":"135","author":"Chu","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib259","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1038\/s41467-023-40680-5","article-title":"Mitochondria are secreted in extracellular vesicles when lysosomal function is impaired","volume":"14","author":"Liang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.031_bib260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ncb2012","article-title":"PINK1\/Parkin-mediated mitophagy is dependent on VDAC1 and p62\/SQSTM1","volume":"12","author":"Geisler","year":"2010","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib261","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1073\/pnas.0913485107","article-title":"Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin","volume":"107","author":"Ziviani","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib262","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib263","doi-asserted-by":"crossref","first-page":"e35878","DOI":"10.7554\/eLife.35878","article-title":"Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila","volume":"7","author":"Cornelissen","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.03.031_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2017.12.008","article-title":"Basal mitophagy occurs independently of PINK1 in mouse tissues of high metabolic demand","volume":"27","author":"McWilliams","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2026.03.031_bib265","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1083\/jcb.201401070","article-title":"Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin","volume":"206","author":"Ashrafi","year":"2014","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib266","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1523\/JNEUROSCI.1198-15.2015","article-title":"The organization of mitochondrial quality control and life cycle in the nervous system in vivo in the absence of PINK1","volume":"35","author":"Devireddy","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib267","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1073\/pnas.1500624112","article-title":"Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration","volume":"112","author":"Stevens","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.031_bib268","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.1093891","article-title":"S-Nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function","volume":"304","author":"Chung","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.031_bib269","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.nbd.2006.10.007","article-title":"Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6","volume":"25","author":"Hoepken","year":"2007","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib270","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1523\/JNEUROSCI.4441-10.2011","article-title":"Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells","volume":"31","author":"Seibler","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib271","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/brain\/awl114","article-title":"PINK1 protein in normal human brain and Parkinson's disease","volume":"129","author":"Gandhi","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib272","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.celrep.2014.05.027","article-title":"Long-term health of dopaminergic neuron transplants in Parkinson's disease patients","volume":"7","author":"Hallett","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib273","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.mvr.2014.01.008","article-title":"Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia\u2013reperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer","volume":"92","author":"Liu","year":"2014","journal-title":"Microvasc Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib274","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release","volume":"75","author":"Hessvik","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib275","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archpsyc.1966.01730070057007","article-title":"Conceptual thinking in psychiatric patients","volume":"14","author":"Salzman","year":"1966","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.apsb.2026.03.031_bib276","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jnc.15288","article-title":"Exosomes in Parkinson disease","volume":"157","author":"Pinnell","year":"2021","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2026.03.031_bib277","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13287-022-03050-4","article-title":"The potential use of mesenchymal stem cells and their exosomes in Parkinson's disease treatment","volume":"13","author":"Heris","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib278","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.214","article-title":"Dicer and microRNAs protect adult dopamine neurons","volume":"8","author":"Chmielarz","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib279","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mcn.2013.10.009","article-title":"Dicer expression is essential for adult midbrain dopaminergic neuron maintenance and survival","volume":"58","author":"Pang","year":"2014","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib280","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/brain\/awaa090","article-title":"Microglial exosomes facilitate alpha-synuclein transmission in Parkinson's disease","volume":"143","author":"Guo","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib281","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/brain\/awv346","article-title":"Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies","volume":"139","author":"Stuendl","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.031_bib282","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/hmg\/ddv633","article-title":"alpha-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease","volume":"25","author":"Spencer","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apsb.2026.03.031_bib283","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41419-019-1404-9","article-title":"Microglia as modulators of exosomal alpha-synuclein transmission","volume":"10","author":"Xia","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib284","doi-asserted-by":"crossref","first-page":"8618","DOI":"10.1523\/JNEUROSCI.0954-20.2020","article-title":"Astrocytes protect human dopaminergic neurons from alpha-synuclein accumulation and propagation","volume":"40","author":"Tsunemi","year":"2020","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib285","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/mds.26686","article-title":"Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease","volume":"31","author":"Fraser","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.apsb.2026.03.031_bib286","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s13311-020-00842-5","article-title":"Long noncoding RNA POU3F3 and alpha-Synuclein in plasma L1CAM exosomes combined with beta-glucocerebrosidase activity: potential predictors of Parkinson's disease","volume":"17","author":"Zou","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.apsb.2026.03.031_bib287","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ymthe.2017.08.017","article-title":"Loss of microRNA-7 regulation leads to alpha-synuclein accumulation and dopaminergic neuronal loss in vivo","volume":"25","author":"McMillan","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib288","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s13311-021-01130-6","article-title":"MicroRNA-7 protects against neurodegeneration induced by alpha-synuclein preformed fibrils in the mouse brain","volume":"18","author":"Zhang","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.apsb.2026.03.031_bib289","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fnagi.2017.00232","article-title":"MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson's disease","volume":"9","author":"Chen","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib290","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13840","article-title":"Regulation of Hsa-miR-4639-5p expression and its potential role in the pathogenesis of Parkinson's disease","volume":"22","author":"He","year":"2023","journal-title":"Aging Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib291","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146331","article-title":"Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson's disease","volume":"1722","author":"Jiang","year":"2019","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib292","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.4103\/1673-5374.368300","article-title":"Exosomes derived from human umbilical cord mesenchymal stem cells alleviate Parkinson's disease and neuronal damage through inhibition of microglia","volume":"18","author":"Zhang","year":"2023","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib293","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12015-014-9551-y","volume":"11","author":"Berg","year":"2015","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib294","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jcyt.2014.07.013","article-title":"Exosomes from dental pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine-induced apoptosis","volume":"17","author":"Jarmalaviciute","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.apsb.2026.03.031_bib295","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.14336\/AD.2020.1221","article-title":"MSC-derived exosomes can enhance the angiogenesis of human brain MECs and show therapeutic potential in a mouse model of Parkinson's disease","volume":"12","author":"Xue","year":"2021","journal-title":"Aging Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib296","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41419-020-2473-5","article-title":"Exosomes derived from mesenchymal stem cells repair a Parkinson's disease model by inducing autophagy","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.03.031_bib297","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/011574888X301827240613063513","article-title":"HucMSCs-derived exosomes protect against 6-hydroxydopamineinduced Parkinson's disease in rats by inhibiting Caspase-3 expression and suppressing apoptosis","volume":"20","author":"Chen","year":"2025","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib298","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12967-023-04638-x","article-title":"miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson's disease model via regulation of Nox4\/ROS\/Nrf2 signaling","volume":"21","author":"He","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib299","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1140481","article-title":"A microRNA feedback circuit in midbrain dopamine neurons","volume":"317","author":"Kim","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.031_bib300","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.omtn.2021.01.022","article-title":"Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson's disease","volume":"23","author":"Li","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2026.03.031_bib301","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3390\/ijms18122698","article-title":"microRNAs in Parkinson's disease: from pathogenesis to novel diagnostic and therapeutic approaches","volume":"18","author":"Leggio","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib302","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41422-024-00971-y","article-title":"Past, present, and future of cell replacement therapy for Parkinson's disease: a novel emphasis on host immune responses","volume":"34","author":"Park","year":"2024","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib303","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0306-4522(93)90340-L","article-title":"Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons--II. Effects on nigral transplants in vivo","volume":"56","author":"Mayer","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2026.03.031_bib304","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nm0195-53","article-title":"Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease","volume":"1","author":"Takayama","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib305","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/exnr.1996.0095","article-title":"Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation","volume":"139","author":"Zeng","year":"1996","journal-title":"Exp Neurol"},{"key":"10.1016\/j.apsb.2026.03.031_bib306","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/mt.2013.180","article-title":"Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model","volume":"21","author":"Redmond","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib307","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.biomaterials.2006.12.021","article-title":"Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats","volume":"28","author":"Tatard","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.03.031_bib308","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s12031-019-01450-5","article-title":"Parkinson's disease-associated changes in the expression of neurotrophic factors and their receptors upon neuronal differentiation of human induced pluripotent stem cells","volume":"70","author":"Novosadova","year":"2020","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib309","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2022.01.013","article-title":"A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells","volume":"29","author":"Moriarty","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib310","doi-asserted-by":"crossref","first-page":"692","DOI":"10.5966\/sctm.2013-0208","article-title":"Human neural stem cells survive long term in the midbrain of dopamine-depleted monkeys after GDNF overexpression and project neurites toward an appropriate target","volume":"3","author":"Wakeman","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib311","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2022.103784","article-title":"BDNF-modified human umbilical cord mesenchymal stem cells-derived dopaminergic-like neurons improve rotation behavior of Parkinson's disease rats through neuroprotection and anti-neuroinflammation","volume":"123","author":"Jiang","year":"2022","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.apsb.2026.03.031_bib312","article-title":"The effect of MSCs derived from the human umbilical cord transduced by fibroblast growth factor-20 on Parkinson's disease","volume":"2016","author":"Jinfeng","year":"2016","journal-title":"Stem Cell Int"},{"key":"10.1016\/j.apsb.2026.03.031_bib313","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/gt.2010.152","article-title":"VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease","volume":"18","author":"Xiong","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib314","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10072-014-1929-8","article-title":"Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson's disease","volume":"36","author":"Jiaming","year":"2015","journal-title":"Neurol Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib315","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.bbmt.2010.06.006","article-title":"Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease","volume":"16","author":"Somoza","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.apsb.2026.03.031_bib316","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10072-010-0385-3","article-title":"The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson's disease rat model","volume":"32","author":"Shi","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1016\/j.apsb.2026.03.031_bib317","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.etap.2013.05.005","article-title":"bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease","volume":"36","author":"Xiong","year":"2013","journal-title":"Environ Toxicol Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.031_bib318","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00429-023-02631-0","article-title":"Extracellular matrix protein anosmin-1 overexpression alters dopaminergic phenotype in the CNS and the PNS with no pathogenic consequences in a MPTP model of Parkinson's disease","volume":"228","author":"Villadiego","year":"2023","journal-title":"Brain Struct Funct"},{"key":"10.1016\/j.apsb.2026.03.031_bib319","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2025.111297","article-title":"Advantages and challenges of using allogeneic vs. autologous sources for neuronal cell replacement in Parkinson's disease: insights from non-human primate studies","volume":"224","author":"Emborg","year":"2025","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.apsb.2026.03.031_bib320","doi-asserted-by":"crossref","DOI":"10.1042\/NS20200083","article-title":"The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease","volume":"5","author":"Qarin","year":"2021","journal-title":"Neuronal Signal"},{"key":"10.1016\/j.apsb.2026.03.031_bib321","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","article-title":"Engineering the next generation of cell-based therapeutics","volume":"21","author":"Bashor","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.03.031_bib322","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.031_bib323","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature09342","article-title":"Epigenetic memory in induced pluripotent stem cells","volume":"467","author":"Kim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.031_bib324","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/ncb2239","article-title":"Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells","volume":"13","author":"Ohi","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib325","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2023.10.003","article-title":"Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity","volume":"30","author":"Gravina","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2026.03.031_bib326","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s40778-022-00221-0","article-title":"Immune editing: overcoming immune barriers in stem cell transplantation","volume":"8","author":"Meissner","year":"2022","journal-title":"Curr Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.031_bib327","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-031-44757-0_8","article-title":"Carotid body dysfunction and mechanisms of disease","volume":"237","author":"Lazarov","year":"2023","journal-title":"Adv Anat Embryol Cell Biol"},{"key":"10.1016\/j.apsb.2026.03.031_bib328","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3892\/etm.2021.10791","article-title":"Fibroblast growth factor 2 suppresses the expression of C\u2013C motif chemokine 11 through the c-Jun N-terminal kinase pathway in human dental pulp-derived mesenchymal stem cells","volume":"22","author":"Kurogoushi","year":"2021","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.apsb.2026.03.031_bib329","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40779-024-00550-7","article-title":"TGF-beta1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson's disease models and patients","volume":"11","author":"Zhuo","year":"2024","journal-title":"Milit Med Res"},{"key":"10.1016\/j.apsb.2026.03.031_bib330","first-page":"768","article-title":"[Scintigraphy in the diagnosis of bone diseases]","volume":"117","author":"Zita","year":"1967","journal-title":"Wien Med Wochenschr"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526001905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526001905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:43:57Z","timestamp":1779191037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526001905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":330,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2211383526001905"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.031","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}